Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $60

Benzinga · 3d ago
Citigroup analyst Albert Hu maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $50 to $60.